Juno Therapeutics bring in new executive vice president
Juno Therapeutics has hired Corsee D. Sanders as its executive vice president and head of development operations. She will step into the role immediately, joining Juno after nearly five years working at Roche as global head of Roche pharmaceuticals clinical operations and external collaboration.
Prior to working in this role, she was held several roles at Genentech for 17 years. In this role, Sanders oversaw the development and submission of Rituxan, Herceptin and Avastin.
“I am delighted to join Juno at an exciting time in the company’s history, and am looking forward to being a part of developing innovative new medicines for patients with difficult diseases,” said Dr. Sanders. “I have been privileged to be a part of bringing highly successful products to market at other companies and am excited to bring that experience to Seattle and Juno.”
“Corsee is a dynamic leader, and a terrific addition to our executive team,” said Hans Bishop, president and CEO of Juno. “Juno’s next phase of growth will benefit from her expertise in the data sciences, her experience leading complex development organizations, and her relentless focus on execution as a strategic advantage.”
- Genentech plans second Phase 3 Alzheimer's trial following endpoint failures
- Mylan’s pathway to launch of biosimilar to Herceptin cleared by Roche
- Genentech oncology head leaves for Bellicum CEO role
- Roche’s ground-breaking MS drug delayed by manufacturing issues
- Genentech announces Bill Anderson as new CEO